Kaos Capital Plans To Nominate Two Independent Directors On Capricor Therapeutics' Board; To Seek Board-Led M&A, Strategic Alternatives Committee
Kaos Capital Ltd. ("Kaos Capital," "we," or "us"), a significant and growing shareholder of Capricor Therapeutics, Inc. (NASDAQ:CAPR) ("Capricor" or the "Company"), today issued a
A big shareholder of Capricor Therapeutics wants to add two new board members who aren't company insiders, and wants the board to explore selling the company or trying new business ideas. When shareholders push for changes like this, it usually means they think the company needs a new direction.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.